Staying Current: Patient Evaluation and Treatment Strategies to Achieve Hemostasis and Improve Outcomes in Hemophilia A and B
Module 2: Role of PK-guided Prophylaxis and Strategies to Improve Patient Adherence

Expert Faculty Author:

Steven Pipe, MD
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Click here for biography

Mark T. Reding, MD
Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Click here for biography

Target Audience
The primary target audience for this initiative consists of hematologists and other hemophilia providers.

Statement of Need/Program Overview
Successful management of hemophilia is dependent on highly specialized, interdisciplinary care, with coordination among various health care providers (HCPs). Research and a burgeoning body of literature have resulted in a deeper understanding of the pathophysiology of hemophilia as well as the intrinsic mechanisms that establish hemostasis. In turn, the therapeutic armamentarium has expanded tremendously over the past several years, necessitating education to fully elucidate the appropriate use of emerging agents to optimize outcomes. To effectively disseminate recent findings and facilitate optimal disease management, hematologists and other HCPs require comprehensive education that increases knowledge and competence in several key areas.

Educational Objectives

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-234-H01-P
Type of ActivityKnowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Working Group Members/Planners

Reported Financial Relationship

Steven Pipe, MD Consulting Fees (ex. advisory boards) - Apcintex, ASC Therapeutics, Bayer Biomarin, Catalyst Biosciences, CSL Behring, GenVentiv, HEMA Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron/Intella, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics, uniQure
Mark T. Reding, MD Grants/Research Support – Bayer, BioMarin (institutional research support)
Consulting fees (ex. Ad boards) – Bayer, BioMarin, CSL Behring, Novo Nordisk, Sanofi Genzyme, Takeda

The PIM planners and managers have nothing to disclose.
The NHF planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

There is no fee for this educational activity.